{"meta":{"query_hash":"d69ee210290e","filters":{"venue":"The Canadian journal of clinical pharmacology"},"cohort_total":4,"direct_labels_cover":0,"predictions_cover":4,"exported":4,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/d69ee210290e","api":"https://metacan.xera.ac/api/v1/cohort?venue=The+Canadian+journal+of+clinical+pharmacology"},"results":[{"id":"W2588891568","doi":"","title":"Chronic Obstructive Pulmonary Disease (COPD) Integrated Care Pathway Project: Evaluation of Patient Outcomes and System Efficiencies.","year":2016,"lang":"en","type":"article","venue":"The Canadian journal of clinical pharmacology","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Seven Oaks General Hospital; Winnipeg Regional Health Authority","funders":"","keywords":"Medicine; COPD; Hyperventilation; Pulmonary disease; Airway obstruction; Airway; Population; Intensive care medicine; Respiratory system; Internal medicine; Emergency medicine; Environmental health; Surgery","score_opus":0.06006549772778429,"score_gpt":0.39057692372586444,"score_spread":0.33051142599808014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588891568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7678229,0.0039030665,0.0038469995,0.007951086,0.00031190115,0.02247147,0.18015078,0.0003862444,0.013155501],"genre_scores_gemma":[0.8449817,0.0021199372,0.02274095,0.0014823327,0.00008462968,0.03716859,0.089070894,0.00011739094,0.0022335525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9821015,0.010079232,0.0017956654,0.00084956054,0.00380759,0.0013665342],"domain_scores_gemma":[0.97425777,0.005211373,0.006604805,0.00097012485,0.007250228,0.005705711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023624027,0.0013332018,0.002363758,0.0018424417,0.0015648081,0.0026983377,0.0024472484,0.0010969929,0.003500099],"category_scores_gemma":[0.034092244,0.0006851285,0.0026956303,0.005018985,0.00063794927,0.0026519115,0.0061086314,0.0019888093,0.00046610174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02024557,0.010141277,0.67193127,0.0054515153,0.0077697756,0.0001652335,0.002572037,0.0059199343,0.0002456123,0.0037082268,0.089531794,0.18231769],"study_design_scores_gemma":[0.008562507,0.0071130483,0.95534384,0.0020261845,0.0036689376,0.00014513185,0.0027922348,0.0065087667,0.00032312018,0.0009486366,0.012453283,0.00011427404],"about_ca_topic_score_codex":0.0848615,"about_ca_topic_score_gemma":0.06928635,"teacher_disagreement_score":0.0848615,"about_ca_system_score_codex":0.011789776,"about_ca_system_score_gemma":0.02781688,"threshold_uncertainty_score":0.16873515},"labels":[],"label_agreement":null},{"id":"W2904203494","doi":"","title":"Introduction to Canada's Progress Toward an Orphan Drug Framework: 2014","year":2014,"lang":"en","type":"article","venue":"The Canadian journal of clinical pharmacology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Medicine; Rare disease; Government (linguistics); Population; Disease; Family medicine; Drug; Pediatrics; Environmental health; Psychiatry; Pathology; Bioinformatics","score_opus":0.3042522085436259,"score_gpt":0.5021960629221933,"score_spread":0.19794385437856743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904203494","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033292978,0.05017268,0.004408387,0.64052415,0.02640454,0.0006496123,0.02096039,0.0010140517,0.25253686],"genre_scores_gemma":[0.065683626,0.073253654,0.03005002,0.42421177,0.010570613,0.00080301793,0.014283136,0.00084644294,0.38029775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98545676,0.0009909136,0.0004348428,0.00077532674,0.009567322,0.0027747983],"domain_scores_gemma":[0.9785978,0.0014064129,0.00056349864,0.0004518133,0.012904469,0.006076022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013442286,0.0009952969,0.00079663354,0.0034465233,0.0059393235,0.013036438,0.0036547938,0.010818776,0.028333588],"category_scores_gemma":[0.018586945,0.0006787996,0.0015791894,0.0040806276,0.0042783953,0.003493131,0.004178746,0.008987918,0.004490298],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003787083,0.00003341072,0.0006017619,0.00021308956,0.0000107466985,0.00008709788,0.00011757648,0.00033846125,0.00011334621,0.068812005,0.9015522,0.028082386],"study_design_scores_gemma":[0.00001631336,0.000012687702,0.0023717203,0.00038710015,0.0000061190162,0.000023304141,0.00008379308,0.00012212626,0.000060675746,0.0021692307,0.9947147,0.00003224269],"about_ca_topic_score_codex":0.9494565,"about_ca_topic_score_gemma":0.9567288,"teacher_disagreement_score":0.8910916,"about_ca_system_score_codex":0.10890839,"about_ca_system_score_gemma":0.28967324,"threshold_uncertainty_score":0.7901894},"labels":[],"label_agreement":null},{"id":"W2904420141","doi":"","title":"Canada's Progress Toward an Orphan Drug Framework: 2014","year":2014,"lang":"en","type":"article","venue":"The Canadian journal of clinical pharmacology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Orphan drug; Medicine; Public relations; Family medicine; Medical education; Political science; Bioinformatics","score_opus":0.3942741165243613,"score_gpt":0.5173967630352366,"score_spread":0.12312264651087534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904420141","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007317801,0.050966226,0.006361694,0.7417027,0.016848905,0.0008011335,0.0070400718,0.00054801523,0.16841356],"genre_scores_gemma":[0.16360591,0.06970882,0.049621604,0.39840317,0.0068025384,0.0008072604,0.007860867,0.00063295075,0.30255687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97030324,0.0030157762,0.00086093263,0.0012896673,0.018217955,0.0063123717],"domain_scores_gemma":[0.9667557,0.0030051789,0.00094622717,0.0008688246,0.016558144,0.011865977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029546302,0.0010732322,0.0013288251,0.0035307456,0.00738108,0.015809685,0.004962259,0.016083697,0.017649341],"category_scores_gemma":[0.026354956,0.0009603428,0.002373105,0.004328365,0.0058873803,0.0041953274,0.005462771,0.009596119,0.001717007],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013095915,0.00013589794,0.0009547896,0.0006741125,0.00006737478,0.00046830272,0.00044653233,0.0015284612,0.00053735916,0.3005412,0.6355666,0.0589485],"study_design_scores_gemma":[0.00006521786,0.00004370422,0.0031015894,0.00040064138,0.000017666813,0.00005816811,0.00020093152,0.0004591865,0.0001887181,0.006571217,0.98883444,0.000058435937],"about_ca_topic_score_codex":0.9565076,"about_ca_topic_score_gemma":0.96063876,"teacher_disagreement_score":0.83457446,"about_ca_system_score_codex":0.16542554,"about_ca_system_score_gemma":0.5235812,"threshold_uncertainty_score":0.9679881},"labels":[],"label_agreement":null},{"id":"W54514359","doi":"","title":"Trends in Use of Clonidine in Ontario Canada, Following Publication of the Women’s Health Initiative Study","year":2004,"lang":"en","type":"article","venue":"The Canadian journal of clinical pharmacology","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Clonidine; Family medicine; Internal medicine","score_opus":0.2842850556273838,"score_gpt":0.4822565635361522,"score_spread":0.19797150790876838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W54514359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91775227,0.005111181,0.00020087381,0.006535683,0.00016153014,0.00010003661,0.05980226,0.00006574026,0.010270502],"genre_scores_gemma":[0.9774393,0.0029448778,0.00030142037,0.0008220339,0.00007486127,0.000053934546,0.011218584,0.000024170206,0.0071208337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979613,0.000101979895,0.00020833817,0.00019702484,0.0009703832,0.0005609767],"domain_scores_gemma":[0.9905137,0.00043915954,0.0024616595,0.000154321,0.004712699,0.0017183693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081506843,0.00023374526,0.00045322525,0.0021501828,0.001801713,0.0018500357,0.0014500832,0.0011736791,0.0022519953],"category_scores_gemma":[0.0066586793,0.00042248596,0.0006814302,0.008608516,0.0006783669,0.000735664,0.00067369273,0.0012565432,0.00031856453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035439464,0.00003825765,0.987538,0.00012740164,0.00012830857,0.00012228538,0.000985703,0.00010731507,0.00022463001,0.00014594918,0.005679816,0.0045480034],"study_design_scores_gemma":[0.000015657664,0.00002254607,0.99646384,0.00003199868,0.000036313617,0.000034401768,0.0007287479,0.000093288974,0.000048079426,0.000011001372,0.002503292,0.000010876491],"about_ca_topic_score_codex":0.99505085,"about_ca_topic_score_gemma":0.99753284,"teacher_disagreement_score":0.03183327,"about_ca_system_score_codex":0.03183327,"about_ca_system_score_gemma":0.05572051,"threshold_uncertainty_score":0.23096764},"labels":[],"label_agreement":null}]}